I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8709-8716

  Lorenzo Zúñiga, Vicente ^a   Llop, Elba ^b   Suárez, Cristina ^b   Álvarez, Beatriz ^b   Abreu, Luis ^b   Espadaler, Jordi ^c   Serra, Jordi ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c AB Biotics   (Spain)

Author keywords

Irritable bowel syndrome; Probiotic combination; Quality of life

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; I 31; LOW DENSITY LIPOPROTEIN; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; I.31;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IRRITABLE COLON; LACTOBACILLUS PLANTARUM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEDIOCOCCUS ACIDILACTICI; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VSI SCALE; ASSESSMENT OF HUMANS; FOLLOW UP; GLOBAL SYMPTOM RELIEF QUESTIONNAIRE; LACTIC ACID BACTERIUM; MEDICATION COMPLIANCE; TREATMENT DURATION; VISCERAL SENSITIVITY INDEX; CLINICAL TRIAL; DIARRHEA; INTESTINE; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; MIDDLE AGED; PEDIOCOCCUS; PHYSIOLOGY; PSYCHOLOGY; SPAIN; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS PLANTARUM; MALE; MIDDLE AGED; PEDIOCOCCUS; PROBIOTICS; QUALITY OF LIFE; QUESTIONNAIRES; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904396512     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8709     Document Type: Article

References (37)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]
2. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-660 [PMID: 10982758]
3. Simrén M, Svedlund J, Posserud I, Björnsson ES, Abrahamsson H. Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases. Clin Gastroenterol Hepatol 2006; 4: 187-195 [PMID: 16469679] (Pubitemid 43199689)
4. Paré P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-1735; discussion 1710-1711 [PMID: 17157129]
5. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, Groves D, Ofman JJ. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005; 11: S17-S26 [PMID: 15926760]
6. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004; 28: 11-15 [PMID: 15041804] (Pubitemid 38325597)
7. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801 [PMID: 21820992 DOI: 10.1053/j.gastro.2011.07.043]
8. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
9. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]
10. Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig 2013; 105: 19-36 [PMID: 23548007]
11. D'Argenio G, Mazzacca G. Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol 1999; 472: 149-158 [PMID: 10736623] (Pubitemid 32202108)
12. Badia X, Herdman M, Mearin F, Pérez I. Adaptación al español del cuestionario IBSQoL para la medición de la calidad de vida en pacientes con síndrome de intestino irritable. Rev Esp Enferm Dig 2000; 92: 637-643 (Pubitemid 33710551)
13. Labus JS, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, Naliboff BD. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004; 20: 89-97 [PMID: 15225175] (Pubitemid 38949810)
14. Müller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, Lefkowitz M. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003; 56: 310-316 [PMID: 12767407] (Pubitemid 36593309)
15. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 547-552 [PMID: 9218081] (Pubitemid 27286957)
16. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-19 [PMID: 11115817] (Pubitemid 32042636)
17. Serra J, Villoria A, Azpiroz F, Lobo B, Santos J, Accarino A, Malagelada JR. Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 401-46, 401-46, [PMID: 20047636 DOI: 10.1111/j.1365-2982.2009.01447.x]
18. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 Suppl 1: i41-i44 [PMID: 12077063] (Pubitemid 34717718)
19. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102: 2767-2776 [PMID: 17900326] (Pubitemid 350179350)
20. Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 2008; 103: 765-774; quiz 775 [PMID: 18177446 DOI: 10.1111/j.1572-0241.2007.01722.x]
21. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, Norton NJ, Whorwell P. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 2011; 106: 1749-1759; quiz 1760 [PMID: 21747417 DOI: 10.1038/ajg.2011.201]
22. Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 455-459 [PMID: 11232690]
23. Carson RT, Tourkodimitris S, Lewis BE, Johnston JM. Small bowel II: PWE-127 Two randomised, double-blind, placebo-controlled phase 3 trials of linaclotide in adults with irritable bowel syndrome: Effects on quality of life. Gut 2011; 61 (Suppl 2): A348-A349
24. Jerndal P, Ringström G, Agerforz P, Karpefors M, Akkermans LM, Bayati A, Simrén M. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179 [PMID: 20367800 DOI: 10.1111/j.1365-2982.2010.01493.x]
25. Sugaya N, Nomura S, Shimada H. Relationship between cognitive factors and anxiety in individuals with irritable bowel syndrome. Int J Behav Med 2012; 19: 308-315 [PMID: 21935740 DOI: 10.1007/s12529-011-9195-0]
26. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881-884 [PMID: 11157169] (Pubitemid 32120760)
27. Eugenio MD, Jun SE, Cain KC, Jarrett ME, Heitkemper MM. Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning. Dig Dis Sci 2012; 57: 1636-1646 [PMID: 22290342 DOI: 10.1007/s10620-012-2047-1]
28. Farndale R, Roberts L. Long-term impact of irritable bowel syndrome: a qualitative study. Prim Health Care Res Dev 2011; 12: 52-67 [PMID: 21426615 DOI: 10.1017/S1463423610000095]
29. Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Dalton CB, Leserman J, Patrick DL, Bangdiwala SI. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007; 102: 1442-1453 [PMID: 17509027] (Pubitemid 46976301)
30. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108: 16050-16055 [PMID: 21876150 DOI: 10.1073/pnas.1102999108]
31. Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-190 [PMID: 16105890] (Pubitemid 43117275)
32. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388] (Pubitemid 40585355)
33. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920 [PMID: 15790844] (Pubitemid 40404694)
34. Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM, Ferreira SH, Cunha FQ, Silva TA, Nicoli JR, Vieira LQ, Souza DG, Teixeira MM. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci USA 2008; 105: 2193-2197 [PMID: 18268332 DOI: 10.1073/pnas.0711891105] (Pubitemid 351439487)
35. Lyte M, Varcoe JJ, Bailey MT. Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. Physiol Behav 1998; 65: 63-68 [PMID: 9811366] (Pubitemid 28511416)
36. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609.e1-3 [PMID: 21683077 DOI: 10.1053/j.gastro.2011.04.052]
37. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010; 11: 32 [PMID: 20334632 DOI: 10.1186/1745-6215-11-32]